Chemomab Therapeutics Reports Q2 2025 Financial Results

Chemomab Therapeutics ( (CMMB) ) has shared an announcement.

On August 14, 2025, Chemomab Therapeutics Ltd. announced its financial results for the second quarter of 2025, revealing a decrease in cash and cash equivalents from $6.07 million at the end of 2024 to $5.45 million as of June 30, 2025. The company also reported a reduction in short-term bank deposits and other receivables, indicating a tighter financial position. This financial update may impact Chemomab’s operational strategies and stakeholder confidence as the company navigates the challenges of its market segment.

The most recent analyst rating on (CMMB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.

Spark’s Take on CMMB Stock

According to Spark, TipRanks’ AI Analyst, CMMB is a Underperform.

Chemomab Therapeutics’ overall stock score is low due to significant financial challenges, including zero revenue and sustained losses. The technical analysis indicates mixed signals but does not currently show strong upward trends. The valuation metrics reflect high risk without profitability or income generation. The company’s future performance heavily relies on its ability to develop and commercialize products successfully.

To see Spark’s full report on CMMB stock, click here.

More about Chemomab Therapeutics

Chemomab Therapeutics Ltd. is a biopharmaceutical company based in Tel Aviv, Israel, focusing on the development of innovative therapeutics for the treatment of fibrotic and inflammatory diseases.

Average Trading Volume: 155,356

Technical Sentiment Signal: Sell

Current Market Cap: $17.45M

For a thorough assessment of CMMB stock, go to TipRanks’ Stock Analysis page.